Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples